Corporate
May 15, 2013
Skadden, Gunderson help seal $1B biopharmaceutical royalty pact
The firms represented South San Francisco-based biopharmaceutical company Theravance Inc. in its $1 billion royalty agreement with Elan Corp. PLC, a deal announced Monday.
Daily Journal Staff Writer
A pair of Bay Area firms represented South San Francisco-based biopharmaceutical company Theravance Inc. in its $1 billion royalty agreement with Elan Corp. PLC, a deal announced Monday.
Skadden, Arps, Slate, Meagher & Flom LLP & Affiliates and Gunderson Dettmer Stough Villeneuve Franklin & Hachigian LLP represented Theravance in the deal.
Per terms of the agreement, Irish dru...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$895, but save $100 when you subscribe today… Just $795 for the first year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In